Cytoagents, Inc.

États‑Unis d’Amérique

Commandez votre montre hebdomadaire Cytoagents, Inc.
Quantité totale PI 15
Rang # Quantité totale PI 103 338
Note d'activité PI 2/5.0    14
Rang # Activité PI 61 046
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

6 1
4 0
4 0
0
 
Dernier brevet 2024 - Car t-cell adjuvant therapies
Premier brevet 2007 - Ep2 and ep4 agonists as agents f...
Dernière marque 2021 - CYTOAGENTS
Première marque 2021 - CYTOAGENTS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Car t-cell adjuvant therapies. Compositions, methods, and kits that can be used to treat cancer ...
2023 Invention Chimeric antigen receptor (car) t-cell adjuvant therapies. Methods, compositions, and kits that c...
Invention Chimeric antigen receptor (car) t-cell adjuvant therapies. Methods, compositions, and kits that ...
Invention Chimeric antigen receptor (car) t-cell adjuvant therapies
Invention Bispecific antibody therapies. Compositions, methods, and kits that can be used to treat cancer, ...
Invention Bispecific antibody therapies. Compositions, methods, and kits that can be used to treat cancer,...
2021 Invention Car t-cell adjuvant therapies. Compositions, methods, and kits that can be used to treat cancer a...
P/S Scientific research and development services in the field of biotechnology
Invention Compositions and methods for treating coronavirus infections. Compositions and methods that can b...
2011 Invention Ep2 and ep4 agonists as agents for the treatment of influenza a viral infection. The present inve...